Navigation Links
Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía
Date:9/2/2014

mo de bajo riesgo de apoplejía y no son candidatos a la terapia anticoagulante con un VKA o un NOAC[4].
  • De los 440 pacientes de GARFIELD-AF con una puntuación CHA2DS2-VASc de 0, 40% que han recibido un anticoagulante (el 32,4% recibieron un VKA y el 7,6% recibieron un NOAC).
  • Los datos confirman además que estos pacientes de bajo riesgo tienden a mostrar menos resultados clínicos adversos, incluyendo un riesgo sustancialmente inferior de todas las causas de muerte, frente a los pacientes con CHA2DS2-VASc ≥1, apoyando la recomendación de las directrices frente al tratamiento de los pacientes de menos riesgo con terapia anticoagulante.
  • Los pacientes mayores es más probable que reciban terapia anticoagulante[7]  

    • Entre los pacientes de GARFIELD-AF, el aumento de la edad se asoció a su vez con el uso anticoagulante oral más frecuente, una mayor incidencia de las co-morbidades y un riesgo más elevado de apoplejía/embolismo sistémico, fallecimiento y eventos hemorrágicos destacados.
    • En pacientes de 65 años o más, el fallecimiento cardiovascular no fue la primera causa de mortalidad.

    Acerca de GARFIELD-AF  

    El registro GARFIELD-AF es una iniciativa independiente de investigación académica. El registro es un estudio prospectivo, internacional, multicentro de observación para los pacientes con AF de nueva diagnosis. Seguirá de forma prospectiva a 50.000 pacientes de al menos 1.000 centros en 35 países de América, Europa occidental y oriental, Asia, África y Australia.

    El conocimiento contemporáneo de la AF se basa en los datos recopilados en los ensayos clínicos
    '/>"/>

    SOURCE GARFIELD-AF
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
    2. Enciclopedia online gratuita sobre el cáncer para la diagnosis y tratamiento del cáncer
    3. Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke
    4. One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines
    5. EpiCast Report: Atrial Fibrillation - Epidemiology Forecast to 2023
    6. Kalila Medical Announces CE Mark Approval For The Vado Steerable Sheath Used During Atrial Fibrillation Procedures
    7. Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
    8. Global Atrial Fibrillation Market Report 2013 - 2019
    9. The Novel Oral Anticoagulants Will Continue to Drive Growth in the Atrial Fibrillation Drug Market
    10. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
    11. Phase IIb Study of Vanoxerine Shows Strong Safety and Statistically Significant Efficacy Signals for Treatment of Atrial Fibrillation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... September 18, 2014 According ... (Surface & Intravascular Systems- Warming & Cooling), Application ... (Surgeon & Anesthesiologist, Nursing & Paramedical Staff) - ... MarketsandMarkets, this report studies the global Temperature Management Market ... The market is expected to reach $2.5 Billion ...
    (Date:9/18/2014)... SAN ANTONIO, Texas , Sept. 18, 2014  Casen ... vessels, skin and muscles to harden.  His case is one ... (GVM) in the world.  The only hospital in ... few in the world, offering treatment with the dual wave-length ... in San Antonio . Using a laser ...
    (Date:9/18/2014)... , Sept. 18, 2014 Research ... "China PTCA Balloon Market Investment Report, 2014-2016" ... as a indispensable medical device in percutaneous coronary intervention ... stent, but also as a device for pre-/post-stent dilatations. ... related to that of PCI. As national ...
    Breaking Medicine Technology:Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3
    ... Medical Systems, a global developer of high-end ultrasound systems, ... number of clinical applications and ranked first or second ... KLAS  "Ultrasound 2011: Innovation on the Move" report. ... monitoring and reporting the performance of information technology and ...
    ... Suneva Medical, a privately-held aesthetic medical device ... aesthetics injectable business with approval from Health Canada ... dermal filler for nasolabial folds or smile line ... long-lasting treatment, Bellafill provides physicians the opportunity to ...
    Cached Medicine Technology:ZONARE Scores in Clinical Applications, Performance and Customer Support & Service in KLAS 2011 Ultrasound Report 2ZONARE Scores in Clinical Applications, Performance and Customer Support & Service in KLAS 2011 Ultrasound Report 3Suneva Medical Announces Canadian Approval of Bellafill™ 2
    (Date:9/18/2014)... Sunnyvale, California (PRWEB) September 18, 2014 ... Dr. Ellen Brown to the position of Chief Medical ... as Medical Director for several Pathways programs including Pathways ... for patients in San Mateo and Santa Clara Counties. ... for the medical component of Pathway’s patient care program. ...
    (Date:9/18/2014)... of the fight for superiority between mutated genes and ... leukaemia, say researchers from the University of Birmingham and ... Reports , investigated Acute Myeloid Leukaemia to understand why ... mature blood cells. , Stem cells in the bone ... The process resembles a production line with genes acting ...
    (Date:9/18/2014)... . In ecology, disease ... pathogen tooth and nail, but rather tolerate it to live (and ... is that the disease only progresses very slowly if at ... , Roland Regoes, a senior scientist at ETH Zurich,s Institute of ... about investigating whether there are infected people who are more tolerant ...
    (Date:9/18/2014)... (PRWEB) September 18, 2014 Clinical trial ... data on the Edema clinical trial scenario. This report ... trials on Edema. It includes an overview of the ... site of trial conduction across the globe. The databook ... their phase, trial status, prominence of the sponsors and ...
    (Date:9/18/2014)... September 18, 2014 This past August, Narconon ... from Roy at the kissing booth during the West Feliciana Animal ... Shelter. “I have loved animals my whole life and have ... those animals being strays who needed a home. Supporting an ... can’t take them all home!” , The CEO of Narconon Louisiana ...
    Breaking Medicine News(10 mins):Health News:Dr. Ellen Brown Promoted to Chief Medical Director at Pathways Home Health & Hospice 2Health News:The war on leukemia: How the battle for cell production could be decisive 2Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2
    ... set by CDC need to be lowered, experts say , ... levels well below those considered safe are still at risk ... , Currently, the maximum safe blood level of lead is ... the U.S. Centers for Disease Control and Prevention in 1991. ...
    ... ... of the advisory board for PerfectServe, a healthcare communications company. , ... Knoxville, TN (PRWeb) Sept. 17, 2009 ... healthcare communications company. The board provides guidance on innovative ways to leverage PerfectServe,s physician-contact ...
    ... PITTSBURGH, Sept. 17 DynaVox Mayer-Johnson, the world,s ... speech, language and learning disabilities, today announced the company received ... Microsoft Corp. This award recognizes DynaVox Mayer-Johnson for its ... products. , , "We are proud to ...
    ... LANSING, Mich., Sept. 17 Neogen Corporation (Nasdaq: NEOG ) announces the ... Neogen Corporation 1st Quarter Results Webcast, When: Thursday, September ... How: Live over the Internet -- Simply log on to ... Address above., Contact: Terry Maynard of Neogen Corporation, +1-800-234-5333., , ...
    ... Chief Operating Officer and Future CEO , , TORONTO, ... MDZ ), a leading provider of products and services ... West, President of MDS Nordion, has been appointed Chief Operating ... Chief Executive Officer of MDS Inc., intends to step down ...
    ... NEW YORK, Sept. 17 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) ... that develops novel therapeutic proteins that disrupt the ... signed a collaboration deal with Beckpharma Ltd. ("Beckpharma") ... treatments. , The two companies are joining forces ...
    Cached Medicine News:Health News:Even Small Amounts of Lead Harmful to Kids 2Health News:Even Small Amounts of Lead Harmful to Kids 3Health News:Alan Weinstein Named Chairman of PerfectServe Advisory Board 2Health News:DynaVox Mayer-Johnson Receives Microsoft Award 2Health News:MDS Announces CEO Transition Plan 2Health News:MDS Announces CEO Transition Plan 3Health News:MDS Announces CEO Transition Plan 4Health News:GENova Biotherapeutics secures new cancer drugs targets 2Health News:GENova Biotherapeutics secures new cancer drugs targets 3
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: